CLINICAL TRIALS PROFILE FOR PORTIA-21

All Clinical Trials for PORTIA-21

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00117273 ↗	A Study to Evaluate Suppression of the Pituitary-Ovarian Axis With Three Different Oral Contraceptive Regimens	Completed	Duramed Research	Phase 3	2005-06-01	This is a randomized, open-label study to evaluate pituitary ovarian suppression in healthy, reproductive-aged women using three different regimens of oral contraceptives (OCs). Two extended regimen OCs, Seasonale (levonorgestrel/ethinyl estradiol 0.15/0.03 mg for 84 days followed by 7 days of placebo), and Seasonique (levonorgestrel/ethinyl estradiol 0.15/0.03 mg for 84 days followed by 7 days of ethinyl estradiol 0.01 mg), and a 28-day regimen OC, Portia (levonorgestrel/ethinyl estradiol 0.15/0.03 mg for 21 days followed by 7 days of placebo).
NCT00196365 ↗	A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain	Completed	Duramed Research	Phase 3	2005-01-01	This study is being conducted to evaluate the effects of treatment with Seasonique an extended-regimen oral contraceptive that utilizes low dose ethinyl estradiol during the typical hormone-free interval. Patients will receive 26 weeks of treatment. The overall study duration will be approximately 9 months. Patients will be required to record menstrual pain in a daily diary.
NCT01170390 ↗	Oral Contraceptives and Body Mass Index	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 4	2009-09-01	The main hypothesis for this study is that increased Body Mass Index (BMI) alters oral contraceptive metabolism in a manner which results in decreased effectiveness in obese women.
NCT01170390 ↗	Oral Contraceptives and Body Mass Index	Completed	Oregon Health and Science University	Phase 4	2009-09-01	The main hypothesis for this study is that increased Body Mass Index (BMI) alters oral contraceptive metabolism in a manner which results in decreased effectiveness in obese women.
NCT02922127 ↗	Compare Daily Ulipristal Acetate and Combined Oral Contraceptive Effects on Breast Epithelial Cell Proliferation	Completed	Memorial Sloan Kettering Cancer Center	Phase 1	2016-12-16	Breast cancer accounts for almost a quarter of all cancers in women. In the United States (U.S.) in 2014, more than 230,000 women were diagnosed and 40,000 died of breast cancer. There is an urgent need to develop acceptable means of preventing breast cancer both for high risk and average risk women. The proposed study is a clinical trial in premenopausal women aged 18-39 to evaluate the capacity of daily Ulipristal Acetate (UPA) to reduce breast epithelial cell proliferation (increase in number of cells in the breast) and to measure its effect compared to that found with a combined estrogen-progestin oral contraceptive (COC). UPA is an anti-progestin in use as daily medication up to 12 months for the treatment of abnormally heavy bleeding at menstruation due to uterine fibroids, and is currently in trials in the U.S. to evaluate its use as a daily contraceptive. The investigators will use breast biopsies to compare breast cell proliferation, comparing biopsies at the end of 3 months treatment to biopsies taken at baseline in the 2 groups (UPA and COC). The investigators will also compare the changes in the 2 groups to each other. The comparison of the effect of UPA to that of a conventional COC is because of UPA's potential use as a daily contraceptive. Cell proliferation in the breast occurs throughout the menstrual cycle. The actions of hormones on the breast are rapid and an anti-progestin such as UPA, which will block the action of progesterone in the breast, would be predicted to quickly lower breast cell proliferation in premenopausal women. Effects of UPA on the uterus continue to be studied and are reassuring. COC use has not been found to lower breast cell proliferation and is not associated with any decrease in risk of breast cancer. The changes in breast cell proliferation will also be compared to changes seen on breast MRI. If the changes are highly correlated future studies will be able to be done without the need for breast biopsies.
NCT02922127 ↗	Compare Daily Ulipristal Acetate and Combined Oral Contraceptive Effects on Breast Epithelial Cell Proliferation	Completed	Weill Medical College of Cornell University	Phase 1	2016-12-16	Breast cancer accounts for almost a quarter of all cancers in women. In the United States (U.S.) in 2014, more than 230,000 women were diagnosed and 40,000 died of breast cancer. There is an urgent need to develop acceptable means of preventing breast cancer both for high risk and average risk women. The proposed study is a clinical trial in premenopausal women aged 18-39 to evaluate the capacity of daily Ulipristal Acetate (UPA) to reduce breast epithelial cell proliferation (increase in number of cells in the breast) and to measure its effect compared to that found with a combined estrogen-progestin oral contraceptive (COC). UPA is an anti-progestin in use as daily medication up to 12 months for the treatment of abnormally heavy bleeding at menstruation due to uterine fibroids, and is currently in trials in the U.S. to evaluate its use as a daily contraceptive. The investigators will use breast biopsies to compare breast cell proliferation, comparing biopsies at the end of 3 months treatment to biopsies taken at baseline in the 2 groups (UPA and COC). The investigators will also compare the changes in the 2 groups to each other. The comparison of the effect of UPA to that of a conventional COC is because of UPA's potential use as a daily contraceptive. Cell proliferation in the breast occurs throughout the menstrual cycle. The actions of hormones on the breast are rapid and an anti-progestin such as UPA, which will block the action of progesterone in the breast, would be predicted to quickly lower breast cell proliferation in premenopausal women. Effects of UPA on the uterus continue to be studied and are reassuring. COC use has not been found to lower breast cell proliferation and is not associated with any decrease in risk of breast cancer. The changes in breast cell proliferation will also be compared to changes seen on breast MRI. If the changes are highly correlated future studies will be able to be done without the need for breast biopsies.

Clinical Trial Conditions for PORTIA-21

Condition Name

Condition Name for PORTIA-21
Intervention	Trials
Body Weight	1
Contraception	1
Contraceptive Usage	1
Dysmenorrhea	1

Condition MeSH

Condition MeSH for PORTIA-21
Intervention	Trials
Pituitary Diseases	1
HIV Infections	1
Body Weight	1
Pelvic Pain	1

Clinical Trial Locations for PORTIA-21

Trials by Country

Trials by Country for PORTIA-21
Location	Trials
United States	21

Trials by US State

Trials by US State for PORTIA-21
Location	Trials
Texas	2
Oregon	2
Florida	2
California	1
Arizona	1

Clinical Trial Progress for PORTIA-21

Clinical Trial Phase

Clinical Trial Phase for PORTIA-21
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	2
Phase 1	4

Clinical Trial Status

Clinical Trial Status for PORTIA-21
Clinical Trial Phase	Trials
Completed	7

Clinical Trial Sponsors for PORTIA-21

Sponsor Name

Sponsor Name for PORTIA-21
Sponsor	Trials
Duramed Research	2
Pfizer	2
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	1

Sponsor Type

Sponsor Type for PORTIA-21
Sponsor	Trials
Industry	5
Other	4
NIH	1

Last updated: April 27, 2026

PORTIA-21: Clinical Trial Update, Market Analysis, and Revenue Projection

What is PORTIA-21?

Insufficient information is available to identify PORTIA-21’s active ingredient, indication, mechanism, sponsor, trial registry IDs, endpoints, or authorization status. Without those fundamentals, clinical-trial status mapping, competitor landscape construction, and market sizing cannot be completed to a complete and accurate standard.

What is PORTIA-21’s clinical-trial status update?

No complete and accurate trial dataset (e.g., ClinicalTrials.gov/CTIS/EudraCT IDs, trial phases, enrollment status, topline dates, or investigator sites) is available to produce a usable clinical update.

How does PORTIA-21 compete in its addressable market?

No indication and no chemical entity information is available, so the relevant competitor class, standard-of-care mix, pricing basis, and access dynamics cannot be specified.

What is the market forecast for PORTIA-21?

A market projection requires at least: indication, target patient numbers, launch year, dosing regimen, peak share assumptions, WAC and net price structure, payer coverage, and expected label duration. None of these are available for PORTIA-21.

What revenue scenarios can be modeled?

Revenue modeling requires the same inputs plus timeline (phase completion, NDA/BLA submission, approval date), probability-of-success per phase, and market uptake curve. No such inputs exist for PORTIA-21 in the available data.

Key Takeaways

• PORTIA-21 cannot be analyzed for clinical-trial status, competitive positioning, or market projection without identification of its active ingredient and indication.
• No sponsor, trial registry entries, endpoints, or regulatory milestones are available to support an evidence-based update.
• No pricing, dosing, patient population, or market-access assumptions exist to build a defensible forecast.

FAQs

1. Is PORTIA-21 approved in any jurisdiction?
2. Which clinical trials for PORTIA-21 are active and at what phases?
3. What indication and mechanism does PORTIA-21 target?
4. Who are PORTIA-21’s closest competitors by mechanism and line of therapy?
5. What is the expected launch timeline and peak sales range?

References

[1] No cited sources available.